Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company, announced on Sunday that it has dosed its first patient with diabetic macular edema (DME) in the phase one study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.
This Phase 1 dose escalations study (CTR20221524) intends to assess the safety and tolerability of intravitreal injection of IBI324 in patients with DME.
IBI324 is a dual-target specific recombinant fully humanised anti-VEGF-A and anti-Ang-2 bispecific antibody developed by the company, which can achieve anti-angiogenesis, vascular stabilisation and inflammation inhibition by blocking both VEGF-A and Ang-2, aiming to provide more potential clinical benefits to DME patients, such as prolonging the dosing interval and improving treatment compliance.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007